Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More